exDNASE Platform Pipeline
Autoimmune & Inflammatory Diseases (e.g., Lupus), Thrombosis, Cancer Metastasis
Phase 1Active
Key Facts
Indication
Autoimmune & Inflammatory Diseases (e.g., Lupus), Thrombosis, Cancer Metastasis
Phase
Phase 1
Status
Active
Company
About Neutrolis
Neutrolis is pioneering a novel therapeutic approach focused on Neutrophil Extracellular Traps (NETs), which are implicated in a range of autoimmune, inflammatory, thrombotic, and oncologic diseases. Founded in 2017 by leading NETosis researchers and backed by $45M in funding, the company has advanced into clinical stages with its exDNASE™ platform. Neutrolis aims to transform patient care by developing precision therapies that degrade pathologic NETs, starting with lupus, offering a potential paradigm shift from broad immunosuppression to targeted disease modification.
View full company profile